Please note: This trial has finished recruiting and is not accepting new participants.

Research Center: Laboratory of Human Behavioral Pharmacology, University of Kentucky
Location: Lexington, Kentucky USA
Lead Doctor: Dr. Craig Rush
Funded By: National Institute on Drug Abuse
IRB Committee: This study has been reviewed and approved by the University of Kentucky Institutional Review Board

Background

Methamphetamine is an addictive drug that can alter the brain’s chemistry. Investigators at the University of Kentucky are studying the effects of 2 FDA-approved medications in combination with methamphetamine.

The knowledge gained from this study will contribute to a better understanding of methamphetamine use and may result in improved therapeutic treatments.

This study seeks men and women who currently use methamphetamine on a regular basis. Participants are required to stay at the University of Kentucky clinical research unit as an inpatient (i.e. reside) for approximately one month and will be compensated for participating in this study.

Why Participate? 

• You will be helping to advance medical research in methamphetamine use, which may result in improved therapeutic treatments.
• You will be compensated for participating in this study.
• You will be reimbursed for travel related to participation in this study.

Your Rights

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the study.

Who Can Participate?

• Men and women ages 18-55 who currently use methamphetamine (meth).
• Willing to participate as an inpatient (i.e. reside) at the research center for approximately one month.
• Not currently seeking or undergoing treatment for stimulant abuse or any other substance abuse.
• Not taking any other illicit substances.
• Willing to refrain from using alcohol and caffeine for the duration of the study.
• Are healthy and have no major disease processes or major psychiatric disorders.